Preclinical evaluation of Sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases

Table 1 Total number of bone metastases in control and Sunitinib groups

Group	Mice Nr.	Total Nr.of metastasis at 4 weeks	Total Nr.of metastasis at 5 weeks
Control	7	14	21
Sunitinib (40 mg/kg/day)	7	12	21

Fluorescent bone metastatic lesions were counted at week 4 and week 5 following tumor cell inoculation. No significant differences in the mean number of metastases was observed between groups.

ISSN: 1471-2407